Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease

BACKGROUND: Ustekinumab was approved in Europe for the treatment of adults with moderate to severe Crohn's disease (CD) in 2016, and there is an urgent need for data on its everyday use. AIM: To obtain data on the daily use of ustekinumab. METHODS: This is a retrospective monocentric study. Pat...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:World J Gastroenterol
Hoofdauteurs: Hoffmann, Peter, Krisam, Johannes, Wehling, Cyrill, Kloeters-Plachky, Petra, Leopold, Yvonne, Belling, Nina, Gauss, Annika
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Baishideng Publishing Group Inc 2019
Onderwerpen:
Retrospective Study
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6710179/
https://ncbi.nlm.nih.gov/pubmed/31496626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v25.i31.4481
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items